Drugs / AGP100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07263139 | Jan 2026 → Jun 2027 expected | catecholaminergic polymorphic ventricular tachycardia | Agiana Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGP100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07263139 ↗ |
| Action | Inhibit | “a selective small molecule inhibitor of phosphodiesterase 2 (PDE2)” NCT07263139 ↗ |
| Modality | Small molecule | “selective small molecule inhibitor” NCT07263139 ↗ |
| Route | Oral | “AGP100 is a capsule for oral administration.” NCT07263139 ↗ |